Sign In
Buy AERI
$15.25
+0 (+0%)
At Close: Feb 17, 2023
Analysts Anticipate Aerie Pharmaceuticals Inc (NASDAQ:AERI) to Announce -$0.79 Earnings Per Share
07:28am, Wednesday, 05'th Aug 2020
Analysts predict that Aerie Pharmaceuticals Inc (NASDAQ:AERI) will post ($0.79) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided e
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Short Interest Update
03:46am, Tuesday, 04'th Aug 2020
Aerie Pharmaceuticals Inc (NASDAQ:AERI) saw a large drop in short interest in July. As of July 15th, there was short interest totalling 8,050,000 shares, a drop of 10.6% from the June 30th total of 9,
Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020
11:30am, Thursday, 30'th Jul 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi
Will Aerie Pharmaceuticals (AERI) Report Negative Q2 Earnings? What You Should Know
04:33pm, Wednesday, 29'th Jul 2020
Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celsion Trial Progress, And Other News: The Good, Bad And Ugly Of Biopharma
03:53pm, Tuesday, 28'th Jul 2020
Celsion advances Phase II advanced ovarian cancer trial. Zentalis inks clinical collaboration with Eli Lilly.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi
Contrasting Aerie Pharmaceuticals (NASDAQ:AERI) & Seattle Genetics (NASDAQ:SGEN)
01:20am, Sunday, 19'th Jul 2020
Aerie Pharmaceuticals (NASDAQ:AERI) and Seattle Genetics (NASDAQ:SGEN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their
Did Hedge Funds Make The Right Call On Aerie Pharmaceuticals Inc (AERI) ?
06:06pm, Friday, 17'th Jul 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile market
Parametric Portfolio Associates LLC Lowers Stock Position in Aerie Pharmaceuticals Inc (NASDAQ:AERI)
04:28am, Sunday, 05'th Jul 2020
Parametric Portfolio Associates LLC reduced its stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 64.6% during the first quarter, according to the company in its most recent 13F filing wit
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Shares Purchased by Geode Capital Management LLC
07:20am, Saturday, 04'th Jul 2020
Geode Capital Management LLC increased its stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 7.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchan
Legal & General Group Plc Has $285,000 Position in Aerie Pharmaceuticals Inc (NASDAQ:AERI)
06:44am, Saturday, 04'th Jul 2020
Legal & General Group Plc lessened its position in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 8.5% in the 1st quarter, Holdings Channel reports. The firm owned 21,085 shares of the company’s stock a
Victory Capital Management Inc. Has $88,000 Stock Holdings in Aerie Pharmaceuticals Inc (NASDAQ:AERI)
06:06am, Saturday, 04'th Jul 2020
Victory Capital Management Inc. lessened its stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 22.2% during the 1st quarter, according to the company in its most recent Form 13F filing wit
Is Aerie Pharmaceuticals a Buy?
12:11pm, Thursday, 02'nd Jul 2020
Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?
Aerie Pharma (AERI) Gets a Buy Rating from Needham - Markets
12:16pm, Friday, 26'th Jun 2020
In a report released today, Serge Belanger from Needham assigned a Buy rating to Aerie Pharma (AERI – Research Report),
The Global Ophthalmology Therapeutics Market will grow by USD 10.42 bn during 2020-2024
